Chudnovsky Yekaterina 4

What Happened
Yekaterina Chudnovsky, a director of Immix Biopharma (IMMX), was granted equity awards on 2026-05-22: 6,250 restricted stock units (RSUs) and a separate 12,500-share derivative award (reported as an acquisition at $0.00). Both grants were reported with a $0.00 per-share price, so no cash changed hands. These are compensatory awards (not open‑market purchases or sales).

Key Details

• Transaction date(s): May 22, 2026; Form 4 filed May 29, 2026 (7 days after the transaction). The filing appears later than the typical 2-business-day Form 4 deadline.
• Awards: 6,250 RSUs (F1) and a 12,500-share derivative award (F3) — both reported as acquisitions at $0.00.
• Vesting:
  • RSUs (6,250): vest in full on the earlier of the one‑year anniversary of the grant or the Issuer’s 2027 annual meeting, subject to continued service (F1).
  • Derivative/option (12,500): vests in substantially equal monthly installments over the 12 months after grant, or any remaining unvested portion vests on the 2027 annual meeting if it occurs earlier, subject to continued board service (F3).
• Shares owned after transaction: Not stated in the reported details.
• Beneficial ownership note: Reporting person is sole member/manager of GKCC, LLC and may be deemed to beneficially own shares held by GKCC (F2).
• Exhibit: Exhibit 24.1 (Powers of Attorney) attached to filing.

Context
These were grant/award transactions (compensation), not purchases or sales; RSUs convert to shares only when they vest, and the option award vests over time, so there was no immediate sale or cash exercise reported. Grants at $0 are common for compensation awards and do not by themselves indicate a market buy or sell signal.